KVUE

#414
Kenvue Inc.
17.3701 USD
+0.55%
부문: 소비방어재
베이스: USD
수익 통화: USD
일일 변동 비율
17.3250
17.3850
년간 변동
14.0200
19.1750
일일 변동
+0.55%
월간 변동
-1.31%
6달 변화
+15.19%
년간 변동율
+15.19%
이전 종가
17.2750
Open
17.3400
Bid
Ask
Low
17.3250
High
17.3850
양
366
Open full chart

Financials

Overview 성명 Statistics Dividends
Quarterly Annual
  • Market Capitalization 33.2938 B
  • Employee 22 K
  • Founded 2022
  • CEO N/A
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry Technology
총매출
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
22.62
Price to sales ratio
2.19
Dividends per share
0.82
Dividend yield %
4.8

Kenvue Inc

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

뉴스